Sepsis & infection

Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study

Crit Care MedPublished Retrospective cohort study

Main finding · ICU admissionResult — go to the resultHazard ratio 0.79 95% CI 0.69–0.91

Authors' conclusion

In patients with type 2 diabetes, SGLT2 inhibitors were independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.

Study context

Population
Adults with type 2 diabetes newly prescribed SGLT2 or DPP-4 inhibitors, 2015–2019, Hong Kong territory-wide registrypropensity-matched cohort
Participants
27,972 adults
Exposure
SGLT2 inhibitors vs DPP-4 inhibitors
  • SGLT2 inhibitorsn = 10,308
  • DPP-4 inhibitorsn = 17,664reference
Outcome
ICU admission
Methodological details1:2 propensity score matched, territory-wide clinical registry, Median follow-up 2.9 years
  • 1:2 propensity score matched
  • Territory-wide clinical registry
  • Median follow-up 2.9 years

Main finding

As reported in the abstract

Hazard ratio

0.79

95% CI 0.69–0.91

P = 0.001

Events by group

SGLT2 inhibitors vs DPP-4 inhibitors
HR 0.79 (95% CI 0.69–0.91); P = 0.001

Observational data: associations, not effects.

Further findings

OutcomeSGLT2 inhibitorsDPP-4 inhibitorsHR (95% CI)P value
All-cause mortality3.1%7.5%0.44 (0.38–0.49)P < 0.001

ICU admissions for sepsis

P = 0.001

Mortality due to sepsis

P < 0.001

Severity of illness on ICU admission (APACHE IV-predicted risk of death)

Lower in SGLT2 inhibitor users

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Crit Care Med. Published 7 April 2023. doi:10.1097/ccm.0000000000005869

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.